Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors
International Journal of Molecular Sciences · 28.11.2023 · 24 (23) · 16872
DOI: 10.3390/ijms242316872 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.11.2023. Verfasst von Milena Urbini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
The outcome of metastatic testicular germ cell tumor patients has been dramatically improved by cisplatin-based chemotherapy combinations. However, up to 30% of patients with advanced disease relapse after first-line therapy and require salvage regimens, which include treatments with conventional-dose chemotherapy or high-dose chemotherapy with autologous stem cell transplantation. For these patients, prognosis estimation represents an essential step in the choice of medical treatment but still remains a complex challenge. The available histological, clinical, and biochemical parameters attempt to define the prognosis, but they do not reflect the tumor’s molecular and pathological features and do not predict who will exhibit resistance to the several treatments. Molecular selection of patients and validated biomarkers are highly needed in order to improve current risk stratification and identify novel therapeutic approaches for patients with recurrent disease. Biomolecular biomarkers, including microRNAs, gene expression profiles, and immune-related biomarkers are currently under investigation in testicular germ cell tumors and could potentially hold a prominent place in the future treatment selection and prognostication of these tumors. The aim of this review is to summarize current scientific data regarding prognostic and predictive biomarkers for salvage therapy in testicular germ cell tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
ORCID-Profile: Milena Urbini, Giuseppe Schepisi, Giorgia Gurioli, Caterina Gianni, Ugo De Giorgi
Förderung
- Italian Ministry of Health
Zitieren
APA
Urbini, M., Bleve, S., Schepisi, G., Menna, C., Gurioli, G., Gianni, C., & De Giorgi, U. (2023). Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors. International Journal of Molecular Sciences, 24(23), 16872. https://doi.org/10.3390/ijms242316872
Vancouver
Urbini M, Bleve S, Schepisi G, Menna C, Gurioli G, Gianni C, et al. Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors. International Journal of Molecular Sciences. 2023;24(23):16872. doi:10.3390/ijms242316872
BibTeX
@article{Urbini2023,
author = {Urbini, Milena and Bleve, Sara and Schepisi, Giuseppe and Menna, Cecilia and Gurioli, Giorgia and Gianni, Caterina and De Giorgi, Ugo},
title = {Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {23},
pages = {16872},
doi = {10.3390/ijms242316872}
}
EUVIMED